IVI is excited to publish our Open-Source Value Platform (OSVP) model focusing on epidermal growth factor receptor (EGFR) positive, non-squamous non-small cell lung cancer (NSCLC), and we invite public comment on the model through April 1, 2019.
Oncology, and specifically lung cancer, is a disease area ripe for value assessment advancement. Therapies are rapidly advancing, often changing the care paradigm and offering patients and their physicians different options. Even with this rapid scientific advancement, for the 45,750 people diagnosed with EGFR+ NSCLC every year, the probability of survival at 5 years is still only 4.7%.
This patient population has a different outlook on value than patients with rheumatoid arthritis. It’s important to understand the patient perspective at the front-end so model development can be specified for individual patients. To that end, we worked with LUNGevity to ensure that patients’ viewpoints were “baked in” from the start. As part of this partnership, we conducted qualitative research with patients to begin including quantitative measurements of factors important to patients.
The research on patient perspectives and the entire OSVP model package – including complete documentation, R package, source code and user interfaces – are available on IVI’s website.
The next step in the model development process requires input from you: stakeholders passionate about value assessment and its impact on decisions for clinicians, patients and payers. We invite public comment through April 1, 2019. Contributions from a wide range of perspectives are a vital component of validating and improving the model. The technical expert panel will review and synthesize comments to develop prioritized recommendations for improvements to the next version of the model, which we will release in 2020.
Having a fully transparent model that allows users to update key assumptions, model structures, and parameter values is a major advance. Further the use of novel value components (e.g., value of hope), incorporating patient preferences through multi-criterion decision analysis (MCDA) framework, and other advances truly demonstrate the latest from the science of value assessment. Go check it out.